STAT+: Up and Down the Ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Source
Stat News
Opens original article in a new tab
AI Bias Analysis
4 models · Takes ~15 seconds

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Source
Stat News
Opens original article in a new tab

(MedPage Today) -- SAN DIEGO -- Two phase I/II studies showed that the investigational RAS(ON) inhibitor daraxonrasib had a manageable safety profile and demonstrated promising efficacy both in combination with chemotherapy and as monotherapy...

(MedPage Today) -- In a spate of recent appearances in Congress, Health Secretary Robert F. Kennedy Jr. recoiled almost every time a lawmaker referred to Medicaid cuts enacted in President Donald Trump's big 2025 tax and spending bill. Throughout...

In today's Morning Rounds newsletter, a new era in GOP drug policy, an international childhood vaccine campaign grows, and more.

President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House